ELDN Eledon Pharmaceuticals, Inc.: Forward P/S Multiple
Eledon Pharmaceuticals focuses on organ rejection therapy via CD40L blockade. The company's projected P/S on GURU.Markets shows valuation volatility, where demonstrates the current level of the metric. Scientific achievements, independent of economic cycles, ensure business stability. Risk mitigation involves seeking a strategic alliance with pharmaceutical behemoths to successfully bring the drug to market.
eledon.com - analytical breakdowns and key metrics (ELDN)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Capital Eledon Pharmaceuticals|ELDN - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Eledon Pharmaceuticals, Inc|ELDN - Company Cumulative Debt|Debt to Book Capitalization Ratio Eledon|ELDN - Company Long-Term Indebtedness|Company Current Liabilities Eledon Pharmaceuticals|Quick Liquidity eledon.com
- business earnings and investment ratios data:
ELDN - Profit After Tax|Projected Future Earnings Eledon Pharmaceuticals|ELDN - Company Value to Net Income|Forward P/E Multiple Eledon Pharmaceuticals, Inc|ELDN - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Eledon Pharmaceuticals Inc.|ELDN - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Eledon Pharmaceuticals|ELDN - Net earnings per share for the last 12 months|Quarterly EPS earnings growth eledon.com|ELDN - Earnings growth in current year|Earnings growth forecast for next year Eledon Pharmaceuticals
- sales revenue and business income indicators:
Initial company analysis:ELDN (Eledon Pharmaceuticals)
The forward P/S ratio relates the current market value of Eledon Pharmaceuticals (ELDN) to expected revenue, reflecting market expectations for the future monetization of its technologies. For a biotech company focused on blocking the CD40L pathway in organ rejection therapy, the forward P/S trend serves as an indicator of investor confidence in the successful capture of market share and the commercial efficiency of new immunological drugs.
Competitor analysis for Eledon Pharmaceuticals
Forward P/S Multiple ARGX (argenx.com)|BioNTech Group (BNTX) - Market Cap to Future Revenue Ratio|ABIVAX - Forward P/S Multiple|ADMA - Forward P/S Multiple|Protagonist (PTGX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Immunovant Inc|Price-to-Projected Revenue Ratio Kiniksa Pharmaceuticals|Grifols Group (GRFS) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Adaptive Biotechnologies Corp (ADPT)|Price-to-Projected Revenue Ratio CLDX (Celldex Therapeutics)|Price-to-Projected Revenue Ratio Aurinia Pharma AUPH|Forward Price to Sales BCRX|VERA: Forward Price-to-Revenue Multiple|Forward Price to Sales DNTH (Dianthus Therapeutics)|Pharvaris N.V. (PHVS) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio AbCellera Biologics (ABCL)|TRML (Tourmaline Bio Inc) - Forward P/S Multiple|Market Cap to Projected Revenue PGEN (Intrexon)|Forward Price-to-Revenue Multiple PHAR (Pharming)|NKTR (Nektar) - Forward Price to Sales|Forward P/S Multiple UPB (upstreambio.com)|ZBIO (Zenas Biopharma Inc) - Future Price to Revenue|IMNM - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Gossamer Bio Inc GOSS|KALV: Forward P/S Multiple|Forward Price-to-Revenue Multiple Septerna Pharma|PVLA (Pieris Corp) - Forward P/S Multiple|Price-to-Projected Revenue Ratio SVRA|Forward P/S Multiple RIGL|Forward Price-to-Revenue Multiple AnaptysBio Corp ANAB|Astria Therapeutics Inc - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio enGene Holdings Inc. (ENGN)|RAPT Therapeutics Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio Aerovate Therapeutics, Inc.|ACRS (Aclaris Therapeutics) - Forward Price-to-Revenue Multiple|KYTX: Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio Tiziana Life Sciences|Cabaletta Bio, Inc (CABA) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple VTYX (Ventyx Biosciences)|Market Cap to Expected Sales Ratio theratech.com|Forward P/S Multiple AVTX (Avalo Therapeutics, Inc.)|AGEN - Forward Price-to-Revenue Multiple|CLYM - Price-to-Projected Revenue Ratio|Future Price to Revenue ZURA|ATYR: Forward P/S Multiple|Adagene Corp (ADAG) - Forward P/S Multiple|Forward Price-to-Revenue Multiple IMA|Shattuck Labs, Inc. - Future Price to Revenue|Price-to-Projected Revenue Ratio Equillium Inc (EQ)|Forward P/S Multiple Connect Biopharma Holdings (CNTB)|Price-to-Projected Revenue Ratio Immunic, Inc. IMUX|Forward P/S Multiple Atara Biotherapeutics ATRA|IFRX - Price-to-Projected Revenue Ratio|XFOR: Price-to-Projected Revenue Ratio|ACET: Forward P/S Multiple|CELU - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio inmunebio.com|Market Cap to Projected Revenue BRNS (barinthusbio.com)|Forward P/S Multiple KZR|Forward P/S Multiple SAB Biotherapeutics, Inc (SABS)|Forward P/S Multiple AKTX (Akari Therapeutics, Plc)|Forward P/S Multiple enlivex.com ENLV|QTTB: Forward Price-to-Revenue Multiple|GOVX - Forward P/S Multiple|Edesa Biotech Inc (EDSA) - Price-to-Projected Revenue Ratio|IBIO - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio carismatx.com|XTLB: Forward Price to Sales|Price-to-Projected Revenue Ratio Bolt Biotherapeutics Inc. (BOLT)|HCW Biologics - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio aptevotherapeutics.com APVO|AIM - Forward Price-to-Revenue Multiple|Aditxt - Forward P/S Multiple|Market Cap to Expected Sales Ratio GRI Bio Corporation GRI|xortx.com (XRTX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio reshapelifesciences.com (HIND)|Price-to-Projected Revenue Ratio Revelation Bio|Market Cap to Future Revenue Ratio Indaptus Therapeutics, Inc. INDP|Price-to-Projected Revenue Ratio BiondVax Pharmaceuticals (SCNI)|Forward Price-to-Revenue Multiple CalciMedica CALI|Price-to-Projected Revenue Ratio Affimed AFMD|ALLK - Forward Price-to-Revenue Multiple|HOOKIPA Pharma, Inc. - Forward P/S Multiple|Forward Price to Sales IGMS (igmbio.com)|ITOS (iTeos Therapeutics, Inc.) - Forward Price-to-Revenue Multiple|Ocean Biomedical Corp (OCEA) - Forward P/S Multiple|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|Forward P/S Multiple thirdharmonicbio.com
